163 related articles for article (PubMed ID: 31015757)
21. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
[TBL] [Abstract][Full Text] [Related]
22. Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists.
Wang CY; Lin YS; Wang YH; Lai CC; Wang HC; Chen L; Yu CJ;
Aging (Albany NY); 2019 Sep; 11(17):6863-6871. PubMed ID: 31509517
[TBL] [Abstract][Full Text] [Related]
23. The rapid effects of budesonide plus formoterol in patients with obstructive airway diseases.
Bayiz H; Ozkaya S; Dirican A; Ece F
Drug Des Devel Ther; 2015; 9():5287-90. PubMed ID: 26451084
[TBL] [Abstract][Full Text] [Related]
24. Tiotropium plus formoterol versus tiotropium alone for stable moderate-to-severe chronic obstructive pulmonary disease: A meta-analysis.
Zou Y; Xiao J; Lu XX; Xia ZA; Xie B; Li J; Chen Q
Clin Respir J; 2018 Jan; 12(1):269-278. PubMed ID: 27402142
[TBL] [Abstract][Full Text] [Related]
25. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.
Cazzola M; Santus P; Di Marco F; Boveri B; Castagna F; Carlucci P; Matera MG; Centanni S
Respir Med; 2003 May; 97(5):453-7. PubMed ID: 12735659
[TBL] [Abstract][Full Text] [Related]
26. Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.
Prescrire Int; 2016 Nov; 25(176):272-277. PubMed ID: 30715829
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
[TBL] [Abstract][Full Text] [Related]
28. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
[TBL] [Abstract][Full Text] [Related]
29. Budesonide and formoterol in a single pressurized metered-dose inhaler for treatment of COPD.
Tashkin DP
Expert Rev Respir Med; 2010 Dec; 4(6):703-14. PubMed ID: 21128746
[TBL] [Abstract][Full Text] [Related]
30. Onset of action of budesonide/formoterol Spiromax(®) compared with budesonide/formoterol Turbuhaler(®) in patients with COPD.
Cazzola M; Ora J; Di Paolo A; Puxeddu E; Calzetta L; Rogliani P
Pulm Pharmacol Ther; 2016 Aug; 39():48-53. PubMed ID: 27344046
[TBL] [Abstract][Full Text] [Related]
31. Budesonide + formoterol delivered via Spiromax
Lewis A; Torvinen S; Dekhuijzen PNR; Chrystyn H; Melani A; Zöllner Y; Kolbe K; Watson AT; Blackney M; Plich A
Respir Med; 2017 Aug; 129():179-188. PubMed ID: 28732829
[TBL] [Abstract][Full Text] [Related]
32. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
Sobieraj DM; White CM; Coleman CI
Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
[TBL] [Abstract][Full Text] [Related]
33. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis.
Wang J; Nie B; Xiong W; Xu Y
J Clin Pharm Ther; 2012 Apr; 37(2):204-11. PubMed ID: 21740451
[TBL] [Abstract][Full Text] [Related]
34. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials.
Halpin DM; Gray J; Edwards SJ; Morais J; Singh D
Int J Clin Pract; 2011 Jul; 65(7):764-74. PubMed ID: 21676119
[TBL] [Abstract][Full Text] [Related]
35. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.
Cates CJ; Lasserson TJ
Sao Paulo Med J; 2010; 128(5):310-1. PubMed ID: 21181075
[TBL] [Abstract][Full Text] [Related]
36. Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK.
Voorham J; Roche N; Benhaddi H; van der Tol M; Carter V; van Boven JFM; Bjermer L; Miravitlles M; Price DB
BMJ Open; 2018 Oct; 8(10):e022051. PubMed ID: 30368448
[TBL] [Abstract][Full Text] [Related]
37. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
[TBL] [Abstract][Full Text] [Related]
38. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
[TBL] [Abstract][Full Text] [Related]
39. Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials.
Li C; Cheng W; Guo J; Guan W
Int J Chron Obstruct Pulmon Dis; 2019; 14():799-808. PubMed ID: 31114181
[No Abstract] [Full Text] [Related]
40. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
Rodrigo GJ; Price D; Anzueto A; Singh D; Altman P; Bader G; Patalano F; Fogel R; Kostikas K
Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]